Adjuvant Nivolumab in Gastric Cancers and CheckMate 8HW

Panelists discuss how they incorporate nivolumab into clinical practice, highlighting specific patient characteristics, biomarkers, and disease features that predict favorable responses to this immunotherapy agent.

EP: 1.Esophageal/Gastric Adenocarcinoma Standard of Care

Now Viewing

EP: 2.Adjuvant Nivolumab in Gastric Cancers and CheckMate 8HW

EP: 3.Gastric Adenocarcinoma: Current Treatment Landscape

EP: 4.Advanced Metastatic Gastric Adenocarcinoma: Treatment Approaches

EP: 5.Second-Line Treatment for Gastric Adenocarcinoma

Recent Videos